Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Chilean Stocks: CFR, Colbun, Ingevec and Salfacorp Were Active

March 22 (Bloomberg) -- The following companies had unusual price changes in Chilean trading. Stock symbols are in parentheses and prices are as of the close in Santiago.

The Ipsa index retreated 0.7 percent to 4,586.78. The MSCI Chile index dropped 1.6 percent to 2,600.19.

CFR Pharmaceuticals SA (CFR CC) rose 2.9 percent to 121.7 pesos, its highest price in almost 10 weeks. The Chilean pharmaceuticals producer plans to invest $20 million in a plant in Argentina, El Mercurio said.

Colbun SA (COLBUN CC) retreated 2.9 percent to 138.2 pesos, the biggest fall in more than five months. Chile’s third-largest power producer fell for a second day after Banco Santander SA cut its rating to the equivalent of sell from hold.

Ingevec SA (INGEVEC CC) advanced 4.3 percent to 50.15 pesos. The Chilean construction company and real estate developer sold 260 million new shares at 48.1 pesos each in the first initial public offering in Chile this year.

Salfacorp SA (SALFACOR CC) plunged 8.2 percent to 1,259.9 pesos and earlier fell a record 13 percent. Chile’s largest builder was the most active stock today by value with 10.9 billion pesos ($22 million) changing hands, more than six times the average volume of the last three months. The Santiago exchange asked the company for information that could explain the fall, it said in a statement posted on its website.

To contact the reporter on this story: Eduardo Thomson in Santiago at ethomson1@bloomberg.net

To contact the editor responsible for this story: David Papadopoulos at papadopoulos@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.